Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.13 USD
-0.12 (-5.33%)
Updated May 24, 2024 04:00 PM ET
After-Market: $2.17 +0.04 (1.88%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ESPR 2.13 -0.12(-5.33%)
Will ESPR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Other News for ESPR
Esperion to Participate in Upcoming June Investor Conferences
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
Esperion, Daiichi announce EC approved label update for NILEMDO, NUSTENDI
Optimistic Outlook for Esperion: Buy Rating Supported by Clinical Success and Market Expansion Potential
Esperion's late stage trial of high cholesterol treatment met main goal